Lung cancer remains a major global health challenge, representing the leading cause of cancer-related mortality worldwide. Despite significant progress in treatment, the prognosis for many patients remains poor due to the high proportion of cases diagnosed at an advanced stage. The articles in this issue span a range of disciplines, highlighting recent advances in low-dose computed tomography (LDCT) screening, radiomics, artificial intelligence-assisted diagnostics, and biomarker-guided tools, along with evolving therapies such as immunotherapy and targeted treatments. Special attention is given to risk-based, population-tailored screening strategies, with a particular focus on non-smokers and underserved high-risk groups. As a diagnostic specialist based in Kaohsiung, Taiwan, I have interpreted over 10,000 LDCT scans and have seen firsthand the vital role of early detection in improving patient outcomes. These experiences reinforce the value of integrating clinical expertise with technological innovation in real-world practice. This Special Issue reflects the collaborative efforts of clinicians, researchers, and public health experts who are dedicated to reducing the global burden of lung cancer. I would like to express my gratitude to the contributing authors and to the editorial and peer-review teams for their commitment to scientific rigor. It is my hope that the insights shared here will inform clinical practice, guide policy, and inspire future research toward better care for patients at risk of lung cancer.
外文書商品之書封，為出版社提供之樣本。實際出貨商品，以出版社所提供之現有版本為主。部份書籍，因出版社供應狀況特殊，匯率將依實際狀況做調整。
無庫存之商品，在您完成訂單程序之後，將以空運的方式為你下單調貨。為了縮短等待的時間，建議您將外文書與其他商品分開下單，以獲得最快的取貨速度，平均調貨時間為1~2個月。
為了保護您的權益，「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。
若要辦理退貨，請在商品鑑賞期內寄回，且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。
